·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
±¤°í¹®ÀÇ
µ¶ÀÚÁ¦º¸
Event
´º½º
Àüü±â»ç
Á¤Ã¥ · ¹ý·ü
Á¦¾à · ¹ÙÀÌ¿À
¾à±¹ · º´¿ø
Ä«µå´º½º
ÆÊTV
À̽´¿µ»ó
DPÃÊ´ë¼®
À̽´Áø´Ü
¾Ë¾Æº¸Àâ
¿ÀÇǴϾð
Àü¹®°¡Ä®·³
µ¥½ºÅ©½Ã¼±
±âÀÚ¼öø
Ưº°±â°í
English
Policy
Opinion
Company
Product
Interview
TVÆÊµµ¶ó
ÆÊTube
ÆÊ¼îÇÎ
³ª´Â¾à»ç´Ù
ÆÊµå¶ó¸¶
ÆÊ¾ÆÄ«µ¥¹Ì
ÃʽÉŬ·¡½º
OTC»ó´ã
Á¦Ç°°ÁÂ
Çмú°ÁÂ
°æ¿µ°ÁÂ
Ä¿¹Â´ÏƼ
ÆÊ¸®Äí¸£Æ®
ä¿ëÁ¤º¸
PHARMARCY
ÀÎÀçÁ¤º¸
DPºÎµ¿»ê
¾à±¹ Q&A
¾à»ç´ëÃâ
¾à»ç½Å¿ë´ëÃâ
¼¼¹«»ó´ã
¼¼¹«·³ë¹«
¹ý·ü»ó´ã
¾à±¹°æ¿µ°úâ¾÷
ÀǾàÀÚ·á½Ç
ÀǾàÇàÁ¤
¾à»ç¾à±¹
ÀǷẴ¿ø
Á¦¾àÀ¯Åë
º¸µµÀÚ·á
ÆÊ½ºÅ¸Å¬·´
ÀÎ»ç · ºÎÀ½
¾à±¹ÀåÅÍ
ȸ»ç¼Ò°³
ȸ¿ø°¡ÀÔ
±¤°í¹®ÀÇ
»ç¾÷Á¦ÈÞ
ÀÎÅͳݽŹ®À±¸®°·É
µ¶ÀÚÁ¦º¸
±âÀÚÀ±¸®°·É
ÀÚÀ²¼¾à¼
¿ø°ÝÁö¿ø¿äû
Event & ¼¼¹Ì³ª
Àüü±â»ç
±×·¡ÇÈ
Á¤Ã¥¡¤¹ý·ü
Á¦¾à¡¤¹ÙÀÌ¿À
¾à±¹¡¤º´¿ø
±âȹ¡¤Å½»ç
Àü¹®°¡Ä®·³
µ¥½ºÅ©½Ã¼±
񃯇
񃯇
ÀǾàǰ
³¹¾Ë½Äº°
µ¥Àϸ®ÆÊ Live Search
´Ý±â
´º½º
>
Àüü ±â»ç
Àüü Çìµå¶óÀÎ ±â»ç
Àüü
|
12-09 (¿ù)
|
12-08 (ÀÏ)
|
12-07 (Åä)
|
12-06 (±Ý)
|
12-05 (¸ñ)
|
12-04 (¼ö)
|
12-03 (È)
¹éÇ÷º´ Ä¡·áÁ¦ 'º¥Å¬·º½ºÅ¸' ±Þ¿© ù °ü¹® Åë°ú
2019-12-06 09:42:40
[µ¥Àϸ®ÆÊ=ÀÌÇý°æ ±âÀÚ] Çѱ¹¾ÖºêºñÀÇ Àç¹ß ¶Ç´Â ºÒÀÀÀÎ ¸¸¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´(CLL, Chronic Lymphocytic Leukemia) Ä¡·áÁ¦ º¥Å¬·º½ºÅ¸Á¤(º£³×ÅäŬ¶ô½º)°¡ ±Þ¿© ù °ü...
ÀÌÇý°æ ±âÀÚ
½ÉÆò¿ø, ¸Þ¸£½º ´ëÀÀ À¯°ø Àå°üǥâ ¼ö»ó
2019-12-06 09:21:16
[µ¥Àϸ®ÆÊ=ÀÌÇý°æ ±âÀÚ] °Ç°º¸Çè½É»çÆò°¡¿ø(¿øÀå ±è½ÂÅÃ)Àº 5ÀÏ ±×·£µå ÇÏ¾æÆ® ÀÎõ È£ÅÚ¿¡¼ ¿¸° 2018³â ¸Þ¸£½º ´ëÀÀ À¯°øÀÚ Æ÷»ó¿¡¼ ¿ì¼ö±â°üÀ¸·Î ¼±Á¤µÅ º¸°Çº¹Áö...
ÀÌÇý°æ ±âÀÚ
°Çº¸°ø´Ü, ¾à°¡Çù»óü°è ǰÁú°æ¿µ½Ã½ºÅÛ ÀçÀÎÁõ ȹµæ
2019-12-06 09:17:34
[µ¥Àϸ®ÆÊ=ÀÌÇý°æ ±âÀÚ] ±¹¹Î°Ç°º¸Çè°ø´Ü(ÀÌ»çÀå ±è¿ëÀÍ)Àº ½Å¾à µîÀÇ °¡°ÝÀ» °áÁ¤ÇÏ´Â ¾à°¡Çù»óü°è¿¡ ´ëÇØ ǰÁú°æ¿µ½Ã½ºÅÛ(ISO9001) »çÈÄ ½É»ç¸¦ Åë°úÇÏ¸é¼ ÀçÀÎ...
ÀÌÇý°æ ±âÀÚ
ÇѾà»çȸ "¼ººÐÇ¥½Ã·Î ø¾à ¾ÈÀü¼º È®º¸, ±¹¹Î ¿ì·ÕÇÏ´Â °Í"
2019-12-06 09:01:11
[µ¥Àϸ®ÆÊ=±è¹Î°Ç ±âÀÚ] ÀÌâÁØ º¸°Çº¹ÁöºÎ ÇÑÀǾàÁ¤Ã¥°üÀÌ Ã¸¾à±Þ¿© ½Ã¹ü»ç¾÷ ¼±½ÃÇà, ÈÄ º¸¿Ï °èȹÀ» ¹àÈ÷¸é¼ ¾ð±ÞÇÑ ³»¿ëÀ¸·Î ÆÄÀåÀÌ Ä¿Áö°í ÀÖ´Ù. ÇѾà»ç´Üü...
±è¹Î°Ç ±âÀÚ
"ºÒ¼ø¹° ´ÏÀÚÆ¼µò ȸ¼ö¹°·® ¾ó¸¶¾ø´Âµ¥...ÆÇ¸ÅÁßÁö¶ó´Ï"
2019-12-06 06:30:48
[µ¥Àϸ®ÆÊ=õ½ÂÇö ±âÀÚ] Á¦¾à»çµéÀÌ ´ÏÀÚÆ¼µòÁ¦Á¦ÀÇ ÆÇ¸ÅÁßÁö Á¶Ä¡¿¡ ´ëÇØ ¾ï¿ïÇÔÀ» È£¼ÒÇϰí ÀÖ´Ù. ºÒ¼ø¹° Ãʰú °ËÃâ Á¦Ç°Àº ´ëºÎºÐ »ý»êÇÑÁö ¿À·¡µÅ ȸ¼ö ¹°·®ÀÌ ...
õ½ÂÇö ±âÀÚ
"¾àÁ¤¿øÀÌ ¹¹±æ·¡"¡¦±è´ë¾÷-¾ç´ö¼÷, ¶Ç ½ÃÀÛµÈ Áø½Ç°ø¹æ
2019-12-06 06:29:39
[µ¥Àϸ®ÆÊ=±èÁöÀº ±âÀÚ] ¾àÁ¤¿ø Àü ÁýÇàºÎ ȸ°è ºÎÁ¤ ÀÇȤÀ¸·Î ½ÃÀÛµÈ ³í¶õÀÌ ±è´ë¾÷ ´ëÇѾà»çȸÀå°ú ¾àÁ¤¿ø Àü ÁýÇàºÎ °£ Á¤Ä¡ ½Î¿òÀ¸·Î ¹øÁö´Â ¸ð¾ç»õ´Ù. ¾ç´ö...
±èÁöÀº ±âÀÚ
'°è¾à±Ý 50¾ï' ÇÑ¹Ì »ç·ÎÀâÀº CCR4 ¸é¿ªÇ×¾ÏÁ¦ ¸Å·ÂÀº?
2019-12-06 06:28:25
[µ¥Àϸ®ÆÊ=¾È°æÁø ±âÀÚ] Çѹ̾àǰÀÌ ¹Ì±¹ ½Å»ý ¹ÙÀÌ¿Àº¥Ã³¿Í ¼ÕÀâ°í »õ·Î¿î ±âÀüÀÇ ¸é¿ªÇ×¾ÏÁ¦ °³¹ßÀ» ÃßÁøÇÑ´Ù. Ãʱâ ÀÓ»óÀ» ÁøÇà ÁßÀÎ FLX475ÀÇ Çѱ¹, Áß±¹ µ¶Á¡ ÆÇ...
¾È°æÁø ±âÀÚ
¸é¿ªÁúȯ½ÃÀå¼ ½Ã¹Ð·¯ Á¤Ã¼...·¥½Ã¸¶ '³ªÈ¦·Î ¼±Àü'
2019-12-06 06:27:54
[µ¥Àϸ®ÆÊ = ±èÁø±¸ ±âÀÚ] ÀÚ°¡¸é¿ªÁúȯ Ä¡·á¿¡ ¾²ÀÌ´Â TNF¾ËÆÄ ¾ïÁ¦Á¦ ½ÃÀå¿¡¼ ±¹»ê ¹ÙÀÌ¿À½Ã¹Ð·¯µéÀÌ »ó¹ÝµÈ ¼ºÀûÀ» ³»°í ÀÖ´Ù. ¼¿Æ®¸®¿ÂÀÇ ¡®·¥½Ã¸¶¡¯°¡ ÁؼöÇÑ ...
±èÁø±¸ ±âÀÚ
¾à±¹ ±Ç¸®±Ý 4¾ï7õ¸¸¿ø Áö±Þ, ¾Ë°íº¸´Ï Àç°³¹ß °Ç¹°
2019-12-06 06:27:12
[µ¥Àϸ®ÆÊ=±èÁöÀº ±âÀÚ] ¾à±¹ÀÌ À§Ä¡ÇÑ °Ç¹°ÀÌ °ð Àç°³¹ß µÈ´Ù´Â »ç½ÇÀ» ¾Ë¸®Áö ¾ÊÀº ä ±Ç¸®±Ý °è¾àÀ» ü°áÇß´Ù¸é, ¾çµµ ¾à»ç´Â ¾ç¼ö ¾à»ç¿¡ Àü¾× ±Ç¸®±ÝÀ» µ¹·ÁÁà...
±èÁöÀº ±âÀÚ
ÈÀÌÀÚ, ¼¼¹øÂ° PARPÀúÇØÁ¦ 'Å»Á¨³ª' ±¹³» ÁøÀÔ ½Ãµ¿
2019-12-06 06:19:53
[µ¥Àϸ®ÆÊ=¾îÀ±È£ ±âÀÚ] ÈÀÌÀÚ°¡ PARAÀúÇØÁ¦ °æÀï¿¡ ÇÕ·ùÇÑ´Ù. 6ÀÏ °ü·Ã¾÷°è¿¡ µû¸£¸é Çѱ¹ÈÀÌÀÚ´Â ÃÖ±Ù ½Ä¾àó¿¡ Æú¸®ÁßÇÕÈ¿¼Ò(PARP, Poly ADP-ribose polymeras...
¾îÀ±È£ ±âÀÚ
1
2
3
4
ä¿ë
¼Óº¸
ÁÖ¹®½Ã °áÁ¦±Ý¾×ÀÇ 5% Áï½Ã ÇÒÀÎ!
¿»·Î¿ì¿¡ÀÌÀ¯ ÇÁ·ÎÆú¸®½º
32%
21,280¿ø
[ij¸®¾î] Ŭ¶óÀ©µå 20L Á¦½À±â
46%
299,001¿ø
[·Îº¸¶ô] Qrevo S ·Îº¿Ã»¼Ò±â
42%
870,000¿ø
[ÆÄ¸¶ÇǾÆ] µÎ³ú¿£ Æ÷½ºÆÄƼµô 30Æ÷
25%
13,585¿ø
[»ïÇö] ¼Òµ¶¿ë¿¡Åº¿Ã
5%
760¿ø
[Çϸ²] ¿ë°¡¸® ġŲ³Ê°Ù 1+1
38%
17,005¿ø
[¸¶´õ½ºÆÊ] ±ÃÁß½ÖȰí 60Æ÷
64%
30,400¿ø
[Ȩ¹ÙÀÌȨ] ³¯°³¾ø´Â ¼±Ç³±â
66%
89,901¿ø
[½ÅÀÏ] ¹«¼± 4ÀÎÄ¡ Å×ÀÌºí ¼±Ç³±â
20%
22,500¿ø
¾ÆÀÌ¿ø Ŭ¸®³Ê¼¼Á¤ 20¸ÅÀÔ
12%
88,825¿ø
[¿À¶óƽ½º] ÀÓÇöõƽ½º 5°³¿ùºÐ
61%
118,750¿ø
¹®¶óÀÌÆ® À¯»ê±Õ
47%
27,930¿ø
¾ß»ý ºôº£¸®&¶óÁ¸® 6ÆÑ
25%
32,300¿ø
[¿À¶óƽ½º] ±¸°À¯»ê±Õ 5°³¿ùºÐ
62%
85,500¿ø
[µð¶óÀÌÇÁ] ºÐ¸®Çü ¼±Ç³±â+°¡¹æÁõÁ¤
68%
41,500¿ø
µ¥Àϸ®¸®¹öÇコ 90Á¤
22%
11,845¿ø
¿Ãµ¥ÀÌ KF94 ¸¶½ºÅ©
8%
250¿ø
[·Îº¸¶ô] F25 RT ¾ÆÄí¾ÆÃ»¼Ò±â
30%
529,000¿ø
¹Ù¸£´Â ÆÄ½º Ä𸵠½ºÆ÷Ã÷°Ö
5%
9,500¿ø
Å»¸ð¼¤Çª1À§¡Ú¸ðÅ彺¼¤Çª
44%
29,450¿ø
[Áß¾Ó·¦] Æ÷½ºÆ®¹ÙÀÌ¿Àƽ½º
47%
32,965¿ø
[¶ó¿¤] À¯±â³ó ¼ø¸é »ý¸®´ë
34%
5,605¿ø
[ÇÏÀÌÀ£] ÃÊÀ¯Ãò¾îºí 120Á¤
45%
36,100¿ø
[µð¶óÀÌÇÁ] 9ÀÎÄ¡ ¼Å§·¹ÀÌÅÍ
48%
23,501¿ø
¾Ë¸² ¡¤ °øÇ¥
±³À° ¡¤ °ÁÂ
¾à±¹ Q&A
Á¢¼ö ¡¤ ¹®ÀÇ
¾Ë¸²
īī¿ÀÀÎÁõÀ¸·Î 1ºÐ¸¸¿¡ Á¾Çռҵ漼 °£Æí¿¹Ãø GO ¢º
¾Ë¸²
°·ÂÇÑ 1À§ÀÇ ºñ°á! ·Î°ÔÀÎÆû ¸ðÙ¾¸àÅ͸® È®ÀÎÇϱ⠢º
¾Ë¸²
[µ¿¾ÆÁ¦¾à]´ç½ÅÀÇ ÇÏ·ç¿¡ ¾î¶² ¸¶±×³×½·ÀÌ ÇÊ¿äÇѰ¡¿ä?
¾Ë¸²
2025 µÑÄÚ¶ô½º ½ÉÆ÷Áö¾ö REPLAY
¾Ë¸²
ÈѽºÅ»¢ç ½´ÆÛÀÚÀÓÀÇ SUPER½ºÆåÆ®·³ & ½Å±Ô Áø¿´ë ¢º
¾Ë¸²
»õ·Î¿öÁø Ç®ÄÉ¾î ÆÐŰÁö&Áø¿´ë POSM ½ÅûÇϱ⠢º
D-191
ij³ª´Ù¾à»ç ½ÃÇè, ÀÌ·¸°Ô ¹Ù²ï´Ù! ( ~12.31 )
D-191
¾à¾÷°è ´ëÇ¥ ±³À°»çÀÌÆ®, ÆÊŬ·¡½º ( ~12.31 )
¼¼¹«»ó´ã
´ç¼Ò¸ð¼ºÀç·á ó¹æÀÇ ¼¼¹«Ã³¸®°üÇØ ±Ã±ÝÇÑ °ÍÀÌ ÀÖ
ÀÚ»ê°ü¸®
Á¾½Åº¸Çè °è¾àÀÚ¿Ü ¼öÀÍÀÚ º¯°æ °¡´ÉÇѰ¡¿ä?
¼¼¹«¡¤³ë¹«
¿¬±Ý°èÁ ¼¼¾×°øÁ¦
¹ý·ü»ó´ã
¾à±¹ °³¼³ °¡´É ¿©ºÎ
¾à±¹°æ¿µ°ú â¾÷
Á¶¸¸°£ Æó¾÷ ¿¹Á¤Àä, Æó¾÷ÀÏÀº ¾à±¹À» ´ÝÀº ³¯
¾à±¹´ëÃâ
¾à±¹¿î¿µÀÚ±Ý
±³À° °Á ¹× ¾Ë¸² ±¤°í ¾È³» ÆäÀÌÁö
¿¬¼ö, ±³À°, ¼¼¹Ì³ª, Çмú°Á ¹× ±â¾÷±³À°, ¸ðÁý
°øÇ¥, Åä·Ðȸ, ÀǾàǰ º¯°æ ¾È³» ¹× °¢Á¾ Çà»ç
¾Ë¸² ±¤°í¸¦ ÇØµå¸³´Ï´Ù.
(Á¢¼ö ¹®ÀÇ ¹Ù·Î°¡±â)
¿À´ÃÀÇ
ÇÖ´º½º
1
'üÁß°¨¼Ò È¿°ú È®ÀÎ'...ÇѹÌ, ±¹Á¦ÇÐȸ¼ ºñ¸¸¾à ÀÓ»ó ¼Ò°³
2
º´¿øÀåÇùÀÇȸ "Á¤ºÎ ÀÇ·á°³Çõ, Áß¼Òº´¿ø »ýÁ¸ À§Çù"
3
´ë±¸½Ã¾à, ÇмúÁ¦ ¿°í ¾à»ç Àü¹®¼º °È ³ª¼
4
ÆòÅýþà, °Åµ¿ ºÒÆí ¾î¸£½Å¿¡ »ç¶ûÀÇ ½Ç¹öÄ« ±âŹ